Expected outcome 1: Determined by the difference in the evolution of clinicas and laboratory conditions between the experimental group and the control group (Placebo) in the treatment of volutear patients for the present clinicas study.The paramentes will be assessed through the following assessments:Titration of IgM and IgG anti-SARS-CoV-2 in patients with confirmed COVID-19 1 month after therapy with infusion with mesenchymal stem cells or placebo associated with convencional therapy;Titration of nonspecific antibodies; lymphocytes and other components of the innate immune system (natural killers; auxiliaries; suppressants; interleukin-6) at the end of the follow-up period (1 month).Computed tomography examinations of the lung should be performed at the beginning of the work; shortly after the diagnosis has been confirmed and at the end of the monitoring period (1 month)

Expected outcome 1: Determined by the difference in the evolution of clinicas and laboratory conditions between the experimental group and the control group (Placebo) in the treatment of volutear patients for the present clinicas study.The paramentes will be assessed through the following assessments:Titration of IgM and IgG anti-SARS-CoV-2 in patients with confirmed COVID-19 1 month after therapy with infusion with mesenchymal stem cells or placebo associated with convencional therapy;Titration of nonspecific antibodies; lymphocytes and other components of the innate immune system (natural killers; auxiliaries; suppressants; interleukin-6) at the end of the follow-up period (1 month).Computed tomography examinations of the lung should be performed at the beginning of the work; shortly after the diagnosis has been confirmed and at the end of the monitoring period (1 month)